Use of EUS-FNA in diagnosing pancreatic neoplasm without a definitive mass on CT

Wang, Wei; Shpaner, Alexander; Krishna, Somashekar G.; Bhutani, Manoop S.; Tamm, Eric P.; Raju, Gottumukkala S.; Xiao, Lianchun; Wolff, Robert A.; Fleming, Jason B.; Lee, Jeffrey H.

doi:10.1016/j.gie.2013.01.040

Cited by 101 publications

(66 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…EUS provides additional information for patients whose initial scans show no lesion or whose lesions have questionable involvement of lymph nodes outside the resection zone (ie, distant disease). [20][21][22][23] Because variations in hepatic arterial anatomy occur in up to 45% of individuals, and EUS is highly operatordependent, EUS is not recommended as a routine staging tool and should not be used to assess vascular involvement.…”

Section: Imaging Evaluationsmentioning

confidence: 99%

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Tempero

Malafa

Al-Hawary

et al. 2017

J Natl Compr Canc Netw

Self Cite

940

897

View full text Add to dashboard Cite

OverviewPancreatic cancer is one of the most common causes of cancer-related death among men and women in the United States. Abstract Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection. J Natl Compr Canc Netw 2017;15(8):1028-1061 doi: 10.6004/jnccn.2017 NCCN Categories of Evidence and Consensus Please NoteThe These guidelines are also available on the Internet. For the latest update, visit NCCN.org.

show abstract

Section: Imaging Evaluationsmentioning

confidence: 99%

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Tempero

Malafa

Al-Hawary

et al. 2017

J Natl Compr Canc Netw

Self Cite

940

897

View full text Add to dashboard Cite

show abstract

“…Several reports show that EUS could detect pancreatic tumors that were not identified on other modalities (Fig. 1) [24, 31–33] and a meta-analysis summarizing these four studies ( n = 206) reported that the sensitivity of EUS for detecting pancreatic malignancy when multidetector CT findings were indeterminate was 85%, with a specificity of 58% [34]. Thus, the high sensitivity of EUS has been repeatedly confirmed.…”

Section: Identification and Characterization Of Solid Pancreatic Massesmentioning

confidence: 89%

Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer

et al. 2018

View full text Add to dashboard Cite

Accumulated evidence has revealed that endoscopic ultrasonography (EUS) has had a great impact on the clinical evaluation of pancreatic cancers. EUS can provide high-resolution images of the pancreas with a quality regarded as far surpassing that achieved on transabdominal ultrasound (US), computed tomography (CT), or magnetic resonance imaging (MRI). EUS is particularly useful for the detection of small pancreatic lesions, while EUS and its related techniques such as contrast-enhanced EUS (CE-EUS), EUS elastography, and EUS-guided fine needle aspiration (EUS-FNA) are also useful in the differential diagnosis of solid or cystic pancreatic lesions and the staging (T-staging, N-staging, and M-staging) of pancreatic cancers. In the diagnosis of pancreatic lesions, CE-EUS and EUS elastography play a complementary role to conventional EUS. When sampling is performed using EUS-FNA, CE-EUS and EUS elastography provide information on the target lesions. Thus, conventional EUS, CE-EUS, EUS elastography, and EUS-FNA are essential in the clinical investigation of pancreatic cancer.

show abstract

“…Pancreatic protocol computed tomography (CT) using a multidetector scanner, which entails multiphasic imaging with thin cuts through the pancreas, is the primary diagnostic tool used to adjudicate this. 4,6 Although endoscopic ultrasound is also frequently used to gain additional information about the tumor and nodal staging of pancreatic cancers, 7,8 as well as to obtain a tissue diagnosis, 9 it should be considered an adjunct to high-quality CT scanning and not serve as the primary basis for staging and deciding on suitability for surgery. 5 Diagnostic laparoscopy can also be considered in the initial staging workup, because the presence of peritoneal metastases may influence treatment decisions, such as the role for, and relative importance of, locoregional therapy.…”

Section: Definition Of Locally Advanced Pancreatic Cancer: Accurate Dmentioning

confidence: 99%

Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma

Pollom¹,

Koong²,

Ko³

2015

Hematology/Oncology Clinics of North America

View full text Add to dashboard Cite

Use of EUS-FNA in diagnosing pancreatic neoplasm without a definitive mass on CT

Cited by 101 publications

References 25 publications

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer

Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma

Contact Info

Product

Resources

About